A Venture Capital firm, with offices in the Eastern US and Europe, currently manages three active funds, two focused on private equities and one focused on public equities. The firm is currently in the process of raising a private equity fund that it plans to have its first close in Sept/Oct 2014. The firm’s private equity funds make investments in the form of preferred equity; the public equity fund invests in the form of PIPEs and public market placements. The size of the firm’s investments is highly varied, as the firm pursues a great variety of opportunities with investments falling anywhere in the €2-€15 million range. The firm is actively seeking new investments in the life science sector, and will consider potential opportunities in Europe and North America.
The firm’s new fund plans to invest broadly in the life sciences across sectors of therapeutics, diagnostics, devices and healthcare IT. The fund is very open across stage, indication and technology types with a slight preference for companies working with platform technologies. The firm also manages a fund that focuses on medical devices, diagnostics and healthcare IT companies with products on the market or close to commercialization. With this fund the firm specifically looks for opportunities that are both increasing quality and reducing the cost of care.
The firm places a considerable focus on technology when vetting deals; the partners of the firm are MDs, PhDs or both. In addition to strong technology the firm prefers to invest in management teams with strong track records and deep domain expertise, preferably with prior experience of achieving success in a venture-backed life science company. The firm generally looks to take a board seat following investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment